PATENT CLAIM ANALYSIS

Application Number: 16067619
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-01
Patent Classification: ["514", "345000"]

Abstract:
The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically-acceptable salts thereof wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.

Claim (Index 16):
A method compound for prophylaxis and/or treatment of disorders associated with aberrant Rho kinase activity, comprising administering to a patient in need thereof a therapeutically effective amount of the pharmaceutical composition of  claim 14 .

Metadata:
- Claim Count in Document: 1.0
- Percentile: 95.0
- Lexical Diversity: 1.2963
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14797414', '14759495', '15890436', '14157564', '14900238']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8218849333009111
- 35 USC 102 Novelty (BERT): 0.5782221833837801
- Combined Prediction Score: 0.797518658309198
- Mean Citation Score: 524.2081519999998
- Max Citation Score: 581.0306400000002
- Similarity Product: 350.87932149487506

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test